IM Cannabis (IMCC)
(Delayed Data from NSDQ)
$2.34 USD
+0.03 (1.30%)
Updated Sep 9, 2024 03:59 PM ET
After-Market: $2.34 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.34 USD
+0.03 (1.30%)
Updated Sep 9, 2024 03:59 PM ET
After-Market: $2.34 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth F Momentum C VGM
Zacks News
IM Cannabis Corp. (IMCC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
IM Cannabis (IMCC) delivered earnings and revenue surprises of 79.76% and 12.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CareCloud, Inc. (CCLD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CareCloud (CCLD) delivered earnings and revenue surprises of 50% and 0.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Prestige Consumer Healthcare (PBH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 4.65% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Q2 Earnings Beat Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 150% and 2.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -26.32% and 0.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
IM Cannabis Corp. (IMCC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
IM Cannabis (IMCC) delivered earnings and revenue surprises of 0% and 14.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IM Cannabis (IMCC) Expands Business in Germany With New Alliance
by Zacks Equity Research
The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
Warby Parker Inc. (WRBY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Warby Parker Inc. (WRBY) delivered earnings and revenue surprises of 100% and 2.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Verano Holdings Corp. (VRNOF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of -100% and 1.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Beats Q2 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 21.29% and 2.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 63.16% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -157.01% and 81.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.53% and 4.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zimmer Biomet (ZBH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 13.86% and 7.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Leafly Holdings, Inc. (LFLY) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Leafly Holdings, Inc. (LFLY) delivered earnings and revenue surprises of -6.25% and 0.68%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
IM Cannabis Corp. (IMCC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of 16.67% and 45.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of 38.46% and 32.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm (VAPO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vapotherm (VAPO) delivered earnings and revenue surprises of -16.88% and 19.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
IM Cannabis Corp. (IMCC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of -700% and 8.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Senestech, Inc. (SNES) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Senestech, Inc. (SNES) delivered earnings and revenue surprises of -10.53% and 24.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 30.93% and 78.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Abbott (ABT): Can Its 3.1% Jump Turn into More Strength?
by Zacks Equity Research
Abbott (ABT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
IM Cannabis Corp. (IMCC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of -550% and 6.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?